199 related articles for article (PubMed ID: 35863357)
21. [Diagnostics and treatment of cholangiocarcinoma].
Mantel HT; Verdonk RC; van Dullemen HM; Gietema JA; Slooff MJ; Porte RJ
Ned Tijdschr Geneeskd; 2008 May; 152(18):1037-41. PubMed ID: 18547024
[TBL] [Abstract][Full Text] [Related]
22. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma.
Verdaguer H; Saurí T; Acosta DA; Guardiola M; Sierra A; Hernando J; Nuciforo P; Miquel JM; Molero C; Peiró S; Serra-Camprubí Q; Villacampa G; Aguilar S; Vivancos A; Tabernero J; Dienstmann R; Macarulla T
Clin Cancer Res; 2022 Apr; 28(8):1662-1671. PubMed ID: 35042699
[TBL] [Abstract][Full Text] [Related]
23. Surgical management of cholangiocarcinoma.
Jarnagin WR; Shoup M
Semin Liver Dis; 2004 May; 24(2):189-99. PubMed ID: 15192791
[TBL] [Abstract][Full Text] [Related]
24. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
25. Emerging molecular therapeutic targets for cholangiocarcinoma.
Ilyas SI; Gores GJ
J Hepatol; 2017 Sep; 67(3):632-644. PubMed ID: 28389139
[TBL] [Abstract][Full Text] [Related]
26. The Molecular Pathogenesis and Targeted Therapies for Cholangiocarcinoma.
Param NJ; Bramel ER; Sia D
Surg Pathol Clin; 2022 Sep; 15(3):529-539. PubMed ID: 36049834
[TBL] [Abstract][Full Text] [Related]
27. A review of the clinical diagnosis and therapy of cholangiocarcinoma.
Yao D; Kunam VK; Li X
J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497
[TBL] [Abstract][Full Text] [Related]
28. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Uson Junior PLS; Borad MJ
Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
[TBL] [Abstract][Full Text] [Related]
29. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians.
Moris D; Palta M; Kim C; Allen PJ; Morse MA; Lidsky ME
CA Cancer J Clin; 2023 Mar; 73(2):198-222. PubMed ID: 36260350
[TBL] [Abstract][Full Text] [Related]
30. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
31. Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance.
Fouassier L; Marzioni M; Afonso MB; Dooley S; Gaston K; Giannelli G; Rodrigues CMP; Lozano E; Mancarella S; Segatto O; Vaquero J; Marin JJG; Coulouarn C
Liver Int; 2019 May; 39 Suppl 1():43-62. PubMed ID: 30903728
[TBL] [Abstract][Full Text] [Related]
32. Role of liver transplantation in the treatment of cholangiocarcinoma.
Singal A; Welling TH; Marrero JA
Expert Rev Anticancer Ther; 2009 Apr; 9(4):491-502. PubMed ID: 19374602
[TBL] [Abstract][Full Text] [Related]
33. Comparison of resection and transarterial chemoembolisation in the treatment of advanced intrahepatic cholangiocarcinoma--a single-center experience.
Scheuermann U; Kaths JM; Heise M; Pitton MB; Weinmann A; Hoppe-Lotichius M; Otto G
Eur J Surg Oncol; 2013 Jun; 39(6):593-600. PubMed ID: 23611755
[TBL] [Abstract][Full Text] [Related]
34. Transplantation for cholangiocarcinoma.
Masuoka HC; Rosen CB
Clin Liver Dis; 2011 Nov; 15(4):699-715. PubMed ID: 22032524
[TBL] [Abstract][Full Text] [Related]
35. Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection?
Miyazaki M; Ito H; Nakagawa K; Ambiru S; Shimizu H; Shimizu Y; Kato A; Nakamura S; Omoto H; Nakajima N; Kimura F; Suwa T
Surgery; 1998 Feb; 123(2):131-6. PubMed ID: 9481397
[TBL] [Abstract][Full Text] [Related]
36. Role of surgery in cholangiocarcinoma: From resection to transplantation.
Neumann UP; Schmeding M
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):295-308. PubMed ID: 25966429
[TBL] [Abstract][Full Text] [Related]
37. The effect of preoperative chemotherapy treatment in surgically treated intrahepatic cholangiocarcinoma patients-A multi-institutional analysis.
Buettner S; Koerkamp BG; Ejaz A; Buisman FE; Kim Y; Margonis GA; Alexandrescu S; Marques HP; Lamelas J; Aldrighetti L; Gamblin TC; Maithel SK; Pulitano C; Bauer TW; Shen F; Poultsides GA; Marsh JW; IJzermans JN; Pawlik TM
J Surg Oncol; 2017 Mar; 115(3):312-318. PubMed ID: 28105651
[TBL] [Abstract][Full Text] [Related]
38. Cholangiocarcinoma of the extrahepatic bile ducts.
Jarnagin WR
Semin Surg Oncol; 2000; 19(2):156-76. PubMed ID: 11126380
[TBL] [Abstract][Full Text] [Related]
39. [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer].
Rademacher S; Denecke T; Berg T; Seehofer D
Chirurgie (Heidelb); 2022 Jul; 93(7):644-651. PubMed ID: 35771272
[TBL] [Abstract][Full Text] [Related]
40. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
